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ABSTRACT
OBJECTIVE.Newborns routinely receive vitamin K to prevent vitamin K deficiency
bleeding. The efficacy of oral vitamin K administration may be compromised in
infants with unrecognized cholestasis. We aimed to compare the risk of vitamin K
deficiency bleeding under different propylactic regimens in infants with biliary
atresia.
PATIENTS AND METHODS. From Dutch and Danish national biliary atresia registries, we
retrieved infants who were either breastfed and received 1 mg of oral vitamin K at
birth followed by 25 g of daily oral vitamin K prophylaxis (Netherlands, 1991–
2003), 2 mg of oral vitamin K at birth followed by 1 mg of weekly oral prophylaxis
(Denmark, 1994 to May 2000), or 2 mg of intramuscular prophylaxis at birth
(Denmark, June 2000–2005) or were fed by formula. We determined the absolute
and relative risk of severe vitamin K deficiency and vitamin K deficiency bleeding on
diagnosis in breastfed infants on each prophylactic regimen and in formula-fed
infants.
RESULTS.Vitamin K deficiency bleeding was noted in 25 of 30 of breastfed infants on 25
g of daily oral prophylaxis, in 1 of 13 on 1 mg of weekly oral prophylaxis, in 1 of
10 receiving 2 mg of intramuscular prophylaxis at birth, and in 1 of 98 formula-fed
infants (P  .001). The relative risk of a bleeding in breastfed compared with
formula-fed infants was 77.5 for 25 g of daily oral prophylaxis, 7.2 for 1 mg of
weekly oral prophylaxis, and 9.3 for 2 mg of intramuscular prophylaxis at birth.
CONCLUSIONS.A daily dose of 25 g of vitamin K fails to prevent bleedings in apparently
healthy infants with unrecognized cholestasis because of biliary atresia. One milli-
gram of weekly oral prophylaxis offers significantly higher protection to these infants
and is of similar efficacy as 2 mg of intramuscular prophylaxis at birth. Our data underline the fact that event analysis
in specific populations at risk can help to evaluate and improve nationwide prophylactic regimens.
VITAMIN K IS essential for effective coagulation, and a deficiency may result in spontaneous life-threatening hemor-rhages.1 As a consequence of the short half-life of vitamin K compared with other vitamins, newborns can become
deficient within days in case of inadequate intake. A bleeding because of vitamin K deficiency (VKD) shortly after birth
is known as hemorrhagic disease of the newborn, or classical VKD bleeding (VKDB). A bleeding after the first week of life
is called “late VKDB.”2 Approximately 50% of infants with late VKDB present with an intracranial hemorrhage.3–5
Breastfeeding is recognized as a major risk factor for both forms of VKD bleedings.4,6,7 This is presumably because
of a lower vitamin K intake in breastfed infants: whereas human milk contains 1 to 2 g/L, most infant formulas are
What’s Known on This Subject
Intramuscular vitamin K prophylaxis at birth efﬁcaciously prevents vitamin K deﬁciency
bleeding in infancy but increasingly encounters parental refusal. We investigated
whether frequent oral prophylaxis prevents vitamin K deﬁciency bleeding by assessing
its prevalence in infants with still-unrecognized cholestatic liver disease.
What This Study Adds
In breastfed infants with cholestatic liver disease, weekly oral (1-mg) vitamin K prophy-
laxis and intramuscular prophylaxis effectively prevented vitamin K deﬁciency bleeding.
In contrast, daily oral prophylaxis (25 g) was associated with frequent (90%) and
severe vitamin K deﬁciency bleeding.
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artificially fortified and contain 50 g/L. A variety of
prophylactic regimens have been introduced to prevent
VKDB in breastfed infants.7–10 A single intramuscular
dose of vitamin K at birth is considered most efficacious,
reducing the incidence of classical, as well as late, VKDB
to 0.2 per 100 000, although recent evidence suggests
that effectiveness may be hampered by a higher risk of
omission of prophylaxis.10–12 Oral administration of vita-
min K at birth prevents classical VKDB but fails to pre-
vent late VKDB, even when administered in very high
dosages.13 Based on these observations, breastfed infants
on oral prophylaxis receive additional doses of vitamin K
in the first months of life.12 This strategy has substan-
tially reduced the incidence of late VKDB.12–14 However,
prophylactic failures have continued to occur, mostly in
infants who later proved to have a cholestatic liver dis-
ease.3,9,15–18
Cholestatic infants are especially sensitive to subopti-
mal vitamin K availability, because the absence of intes-
tinal bile greatly reduces the absorption of vitamin K and
other fat-soluble vitamins.19,20 The repeated occurrence
of prophylactic failures in infants with unrecognized
cholestatic liver disease warrants careful evaluation of
the efficacy of vitamin K prophylactic regimens in these
infants. National registries for biliary atresia provide a
unique opportunity to quantitate the efficacy of vitamin
K prophylaxis in a well-defined and homogeneous pop-
ulation of cholestatic infants. These registries allow us to
determine the absolute risk of VKDB in breastfed infants
under different prophylactic regimens. Moreover, these
risks can be weighed against the risk in formula-fed
infants. We performed a retrospective cohort study in
Dutch and Danish infants with biliary atresia to compare
the efficacy of frequent (daily or weekly) oral vitamin K
prophylaxis with intramuscular (IM) vitamin K prophy-
laxis at birth.
METHODS
Study Population
Data from Dutch biliary atresia patients born between
1991 and 2003 were obtained from the Netherlands
Study Group for Biliary Atresia Registry, a joint effort of
the Dutch Society for Pediatrics and the Dutch Society
for Pediatric Surgery. Danish biliary atresia patients born
between 1994 and 2005 were retrieved from the Uni-
versity Hospital of Copenhagen (Rigs Hospital) Depart-
ment of Pediatric Surgery. The Rigs Hospital is the Dan-
ish national referral center for patients with suspected
biliary atresia and for Kasai hepatoportoenterostomy.
Routine vitamin K prophylaxis aims to prevent VKDB
in apparently healthy term infants. Infants with a gesta-
tional age of 37 weeks or a birth weight of 2000 g
were excluded, because these infants routinely receive
additional vitamin K prophylaxis. Patients hospitalized
from birth until diagnosis were also excluded, because
they may have received additional vitamin supplements,
as well as other diets. Late VKDB has been defined to
occur after the first week of life and before the age of 6
months.2 Accordingly, infants were excluded if cholesta-
sis was diagnosed before the first week of life or after the
age of 6 months.
Patient files were reviewed to obtain relevant demo-
graphic data and clinical characteristics. Age at diagnosis
was defined as the age that cholestasis was first diag-
nosed. Cholestasis was defined as a total serum bilirubin
concentration of 50 mol/L with a direct fraction of
20%. Clinical or biochemical indications for a VKD at
diagnosis were recorded, as well as information on (ad-
herence to) vitamin K prophylaxis. Infants were catego-
rized as “breastfed” if they had received exclusively
breastfeeding from birth onward. All of the other infants
were categorized as “formula fed.”
Vitamin K Prophylaxis
Since 1990, all of the infants born in the Netherlands
receive an oral dose of 1 mg of vitamin K directly after
birth. On breastfeeding, parents are advised to give their
child a daily oral dose of 25 g of vitamin K from the
second week of life until the end of the 13th week. For
daily dosing of vitamin K, a dietary supplement is used
in which vitamin K is solved in arachid oil. The vitamin
K prophylaxis can be stopped earlier if breastfeeding
accounts for 50% of the feedings.16
In Denmark, 2 different vitamin K prophylaxis regi-
mens have been used. Between 1994 and June 2000, all
of the infants born after an uncomplicated delivery re-
ceived an oral dose of 2 mg of vitamin K directly after
birth. In the case of a complicated delivery (forceps or
vacuum extraction, cesarean section, perinatal asphyxia,
and prematurity) the vitamin K dose of 2 mg was ad-
ministered intramuscularly.13 Subsequently, breastfed
infants received a weekly oral dose of 1 mg of vitamin K
(Konakion EL, Roche, Basel, Switzerland). Parents were
advised to continue vitamin K administration as long as
infants were breastfed for 50% of their daily feedings.
Since June 2000, the Danish prophylactic regimen has
consisted of a single IM dose of 2 mg of vitamin K
(Konakion MM, Roche, Basel, Switzerland) after birth
for all of the infants.13
In both countries, formula-fed infants only receive
vitamin K prophylaxis directly after birth. Thereafter,
they are expected to receive sufficient amounts of vita-
min K, because the formula feedings commercially avail-
able in these countries contain 50 g of vitamin K per
liter.21 Data from formula-fed infants receiving oral pro-
phylaxis at birth from both countries were used to assess
the efficacy of formula feeding.
VKD
We calculated the prothrombin ratio (PR) at initial diag-
nosis to be able to compare coagulation parameters from
different hospitals in both countries and used it to assess
the presence of VKD. The PR was determined as follows.
If available, the international normalized ratio was used
as PR. If a prothrombin percentage had been deter-
mined, the international normalized ratio was estimated
from the conversion table supplied by the producer (Axis
Shield, Oslo, Norway). In case of a prothrombin time
(PT) in seconds, the PR was determined as follows: PR 
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PTpatient:PTcontrol. If a PTcontrol was not determined by the
laboratory, it was defined as the mean of the provided
reference range.
VKD was defined as a PR of1.5 in combination with
a normal thrombocyte count. A PR above this threshold
is rare in healthy infants after the first week of life.22,23
Significant PR elevations in otherwise healthy biliary
atresia infants are unlikely to be because of other caus-
es.24 A PR of 4 was designated as “severe” VKD. VKDB
was defined as bruising, bleeding, or intracranial hem-
orrhage in combination with a PR of 4 in any infant
between 8 days and 6 months of age and normalizing
after administration of vitamin K.2 The number of bleed-
ings and their locations were noted.
Statistical Analysis
We performed a 2-way analysis of variance of clinical
and biochemical parameters with a normal distribu-
tion pattern to test for statistical differences between
groups. Kruskal-Wallis analysis was used for those
parameters with a nonnormal distribution. In case
statistical significant differences were found, a Bonfer-
roni test for multiple comparisons or a Mann-Whitney
U test was used for posthoc analysis, respectively.
Fisher’s exact test was performed to determine statis-
tical significance between groups in case of dichoto-
mous parameters. The relative risks (RRs) and 95%
confidence intervals (CIs) for VKDB and biochemical
levels of VKD were calculated.
We performed conditional logistic regression analysis
to assess potential confounding. First, all of the clinical
and biochemical parameters were considered as possible
confounders and included, 1 by 1, as covariates. Risk
factors that changed the odds ratio (OR) by 10% were
added to a model and were maintained in the final
model if they induced a change of 10% in that model.
SPSS 12.01 (SPSS Inc, Chicago, IL) was used for all of the
analyses.
RESULTS
Between January 1991 and December 2003, 139 biliary
atresia patients were included into the Netherlands
Study Group of Biliary Atresia Registry (Table 1). Sev-
enteen of these infants did not meet the inclusion crite-
ria; 9 had stayed in a hospital from birth until diagnosis,
7 were born outside of the Netherlands, and 1 was
excluded because of prematurity. Thirty (25%) of the
remaining 122 infants were exclusively breastfed, and
88 (72%) were formula fed. In 4 infants, the type of
feeding was not documented. In total, 63% of all of the
infants received any amount of breastfeeding, which is
similar to the 51% to 63% of infants using breastfeeding
at the age of 6 weeks in the Netherlands from 1991 to
2003, as known from epidemiologic data (www.cbs.nl/
statline).
A total of 46 patients born between January 1994 and
December 2005 were reported to the Danish Biliary
Atresia Registry. Nine infants were excluded; 6 had
stayed in a hospital from birth until diagnosis and 3 were
excluded because of prematurity. In addition, 5 infants
born before June 2000 were excluded because vitamin K
was administered IM after a complicated delivery.
Twenty three of the remaining 32 infants (77%) were
breastfed, of which 13 were born before June 2000.
Clinical Characteristics
Infants from both countries were categorized according
to the type of prophylaxis that they received. Table 2
summarizes the clinical characteristics in breastfed in-
fants on frequent (daily or weekly) oral or IM prophy-
laxis and the combined group of formula-fed infants.
Overall, breastfed infants had a slightly, but significantly,
higher birth weight than formula-fed infants. Cholestasis
was found 14 days earlier in Dutch breastfed infants
compared with formula-fed infants (P  .001). The age
at diagnosis correlated significantly with parameters of
cholestatic liver disease.
TABLE 1 Patients and Populations
Variable Netherlands (1991–2003) Denmark (1994–June 2000) Denmark (July 2000–2005)
Prophylactic regimen 1 mg oral at birth 25g daily oral 2 mg oral at birth 1 mg weekly oral 2 mg IM at birth
No. of live birthsa 2 963 609 440 529 356 602
Enlisted in biliary atresia registry, n 139 26 20
Incidence of biliary atresia 1:21 321 1:16 943 1:17 830
Excluded, n
Born abroad 7 0 0
Hospitalized from birth 9 1 5
Premature 1 2 1
Unknown feeding typeb 4 0 0
Complicated deliveryc 5
Formula fedd 4
Included, n 118 18 10
Breast fed 30 13 10
Formula fed 88 5
a Data on Dutch and Danish live births were derived from the Central Bureau of Statistics (http://statline.cbs.nl) and Denmark Statistics (www.dst.dk/HomeUK.aspx).
b Type of prophylaxis could not be determined.
c Patients received 2 types of prophylaxis: IM and weekly oral.
d Patients received 2 types of prophylaxis: IM and formula.
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VKD in Breastfed Infants
VKDwas evident in all (30 of 30) Dutch breastfed infants
with biliary atresia (Table 3). VKD was severe in 29 of 30
(96%), and this was associated with a VKDB in 25 of 30
(83%). Fifteen infants (50%) had multiple bleedings. An
intracranial hemorrhage was diagnosed in 13 of 30
(43%) Dutch breastfed infants. In contrast, VKDB oc-
curred in only 1 of the Danish infants after weekly oral
prophylaxis (1 of 13 [8%]) and also in 1 after IM pro-
phylaxis (1 of 10 [10%]; each P  .001 compared with
the Dutch daily oral prophylaxis). No intracranial hem-
orrhages were documented in Danish breastfed infants
on either regimen. Nevertheless, VKD was a relatively
frequent finding, present in 5 of 13 (39%) of the Danish
breastfed infants on weekly oral prophylaxis and in 3 of
10 (30%) of the infants on IM prophylaxis at birth.
Efﬁcacy of Vitamin K Prophylaxis in Breastfed Infants:
ComparisonWith Formula Feeding
We compared the risk of (severe) VKD and VKDB in
breastfed infants receiving frequent oral or IM prophylaxis
with the risk in formula-fed infants (Table 4). Only 1 of the
93 formula-fed infants had a VKDB. Dutch breastfed in-
fants were poorly protected against VKDB compared with
formula-fed infants, with a relative risk for a VKDB of 77.5
(95% CI: 11.0–548.0). Similar results were obtained when
only Dutch formula-fed infants were used for comparison
(RR: 73.3; 95% CI: 10.4–518.0).
Both Danish regimens offered substantially better
protection. Nevertheless, the risk of a severe VKD in
Danish breastfed infants on either IM or weekly oral
prophylaxis was still clearly elevated when compared
with formula-fed infants. The risk for VKDB was not
significantly different between Danish breastfed and for-
mula-fed infants.
To evaluate whether the occurrence of VKDB could
be the result of diagnostic delay, the age of diagnosis in
infants with VKDB was compared with infants without
VKDB. Instead, as depicted in Fig 1, infants with VKDB
presented significantly earlier, suggesting that a VKDB
leads to an earlier diagnosis.
Theoretically, other clinical characteristics could have
served as confounding factors for the higher risk of
VKDB in Dutch breastfed versus formula-fed biliary
atresia infants. However, conditional logistic regression
resulted in an initial OR of 435 (95% CI: 48.6–3897.0)
for VKDB in breastfed versus formula-fed infants and an
adjusted OR of 933 (95% CI: 28.7–30 371.0). Logistic
regression revealed that female gender was a risk factor
for VKDB (OR: 4.1; 95% CI: 1.5–11.3). However, female
gender was not significantly associated with (severe)
VKD.
DISCUSSION
Our data show that the Dutch vitamin K prophylactic
regimen does not protect breastfed infants with biliary
atresia. More than 80% of these infants had developed a
VKDB at the time that cholestasis was diagnosed. The
clinical significance of this is illustrated by the fact that
43% of breastfed infants with biliary atresia presented
TABLE 2 Comparison of Characteristics for Each Type of Prophylaxis
Characteristic 25g Daily Oral
(n 30)
1 mgWeekly Oral
(n 13)
2 mg IM at Birth
(n 10)
Formula Fed
(n 93)
P
Male gender, n (%)a 10 (33) 7 (54) 6 (60) 49 (53) .260
Birth weight, mean SD, gb 3351 404 3517 347 3304 525 3115 629 .050
Age at diagnosis, median (interquartile range), dc 35 (28–43) 46 (26–59) 54 (16–70) 49 (38–61) .001
Weight at diagnosis, mean SD, gb 3959 423 4531 922 4576 1186 4150 845 .080
Bilirubin total, median (interquartile range),mol/Lc 147 (104–202) 153 (97–289) 197 (140–304) 178 (122–257) .080
Bilirubin direct, median (interquartile range),mol/Lc 98 (71–135) 124 (85–193) 135 (82–182) 127 (93–176) .130
Bilirubin indirect, median (interquartile range),mol/Lc 41 (27–76) 193 (152–233) 181 (125–237) 154 (125–180) .090
ASAT, median (interquartile range), U/Lc 144 (94–235) 131 (103–154) 86 (63–150) 104 (84–133) .420
ALAT, median (interquartile range), U/Lc 88 (66–135) 52 (34–111) 49 (43–88) 37 (25–62) .080
Data show infants with biliary atresia. All of the infants in the ﬁrst 3 columns were exclusively breastfed. ASAT indicates aspartate aminotransferase; ALAT, Alanine aminotransferase.
a P value was determined by using Fisher’s exact test.
b P value was determined by using ANOVA.
c P value was determined by using Kruskal-Wallis test.
TABLE 3 Risk of VKD in Breastfed Infants With Biliary Atresia Under Different Prophylactic Regimens
Variable 25g Daily Oral,
n/N (%)
1 mgWeekly Oral,
n/N (%)
2 mg IM at Birth,
n/N (%)
P Daily Versus
Weekly Oral
Daily Oral Versus
IM at Birth
RR 95% CI RR 95% CI
VKDa 30/30 (100) 5/13 (39) 3/10 (30) .001 2.6 1.3–5.2 3.3 1.3–8.6
Severe VKDa 29/30 (97) 3/13 (23) 2/10 (20) .001 4.2 1.5–11.3 4.8 1.4–16.7
VKDB 25/30 (83) 1/13 (8) 1/10 (10) .001 10.8 1.6–71.7 8.3 1.3–53.9
Intracranial hemorrhage 13/30 (43) 0/13 (0) 0/10 (0) .001 b b b b
Pwas determined by using Fisher’s exact test.
a VKD was deﬁned by a normal thrombocyte count and PR of1.5, severe VKD by a PR of4.
b Data cannot be computed. P 1.0 for all of the comparisons between weekly oral and IM prophylaxis.
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with an intracranial hemorrhage. The risk of VKDB in
Dutch breastfed infants with biliary atresia was 8 to 10
times higher than in breastfed infants on either weekly
oral prophylaxis or IM prophylaxis at birth and 80
times higher than in formula-fed infants.
The design of the present study was set out to minimize
the risk of bias. To reduce selection bias, we focused on
infants with biliary atresia, a rarely missed diagnosis for
which national registries are available. The incidence of
biliary atresia in the Netherlands and Denmark, calculated
from our present study, was 1:21 321 and 1:17 329, re-
spectively. These incidences are in close agreement with
the earlier reported incidence of 1:20 000.25 Theoretically,
the high overall risk of VKDB in this study could be attrib-
uted to a higher detection rate of mild cases. However, the
observed fraction of infants with VKDB presenting with an
intracranial hemorrhage was in line with previous data,3,5
which makes this option unlikely. We excluded infants
who might have received additional vitamin K, such as
preterm infants, to reduce the risk of misclassification. Al-
though some clinical parameters differed significantly be-
tween groups, these parameters did not significantly influ-
ence the risk of VKDB in breastfed infants on conditional
logistic regression analysis.
Our definition of a VKD was based on an elevated PR
in the absence of thrombocytopenia, parallel to the case
definition of VKDB. Although this definition largely ex-
cludes diffuse intravascular coagulation, it does not ex-
clude other causes of PR elevation and may, therefore,
give rise to misclassification. However, we do not con-
sider this a major concern in the context of infants with
biliary atresia, a condition characterized by poor vitamin
K absorption. Moreover, liver dysfunction in biliary atre-
sia is unlikely to cause a PR of 1.5 during the first
months of life.24 Similarly, a “physiologic” PR of 1.5 is
rare after the first week of life.22,23 We also analyzed the
data using a higher cutoff value of the PR (2), but the
results were essentially identical (Table 4).
The observed failure of the current Dutch regimen to
protect breastfed biliary atresia infants contrasts with
surveillance data obtained after introduction of this reg-
imen.12 These surveillance data indicate that daily oral
vitamin K prophylaxis was of similar efficacy as IM
prophylaxis. This conclusion was supported by the ob-
servation that Dutch breastfed infants had adequate vi-
tamin K levels throughout the first 3 months of life and
that their coagulation parameters remained within nor-
mal limits.26 However, these studies focused on healthy
infants and did not address the efficacy of vitamin K
prophylaxis in conditions with poor absorption of vita-
min K, such as that observed in cholestatic infants. This
approach may give rise to equivocal results: recent sur-
veillance data from the Netherlands under the same
prophylactic regimen seem to contradict the previous
findings, with a reported incidence of 3:100 000.27 Five
of 6 reported failures had an unrecognized cholestatic
liver disease.
Reliable information on the efficacy of prophylactic reg-
imens in high-risk infants is of increasing importance, be-
cause these infants now represent the vast majority of
prophylactic failures.3,9,15 Themethod presented here, com-
parison of well-delineated and homogeneous risk popula-
tions, may be very helpful in this respect. In contrast to
nationwide surveillance studies, which are sensitive to un-
derreporting,3,12 it seems to be a reliable method to detect
prophylactic failures. The presently applied method not
only allows us to determine the number of failures but also
to calculate the failure rate, because clinical information
can be obtained from all of the infants within such a
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FIGURE 1
Age at presentation in Dutch and Danish infants with biliary atresia. Infants with VKDB
presented signiﬁcantly earlier than those without VKDB (34 vs 50 days; P .001). There
was a signiﬁcant interactionwith feeding type (R 0.609; P .001). Twenty-seven (96%)
of the 28 infants with VKDB and 26 (14%) of the 118 infants without VKDBwere breastfed
(P .001).
TABLE 4 RR of VKD in Breastfed Infants With Biliary Atresia Despite Prophylaxis ComparedWith Formula-Fed Infants
Variable VKDa Severe VKD VKDB
RR 95% CI RR 95% CI RR 95% CI
Formula fed (n 93)b 1.0 NA 1.0 NA 1.0 NA
Breastfed2 mg IM at birth (n 10)c 4.7 1.4–15.8 18.6 1.9–187.0 9.3 0.6–138.0
Breastfed1 mg weekly oral (n 13)d 6.0 2.1–16.8 21.5 2.4–1910 7.2 0.5–108.0
Breastfed25g daily oral (n 30)e 15.5 7.2–33.6 89.9 12.7–632.0 77.5 11.0–548.0
NA indicates not applicable. VKD was deﬁned by a normal thrombocyte count and a PR of1.5, severe VKD by a PR of4.
a Similar results were found when a PR of2 was chosen to deﬁne VKD; RR for IM prophylaxis was 6.2 (95% CI: 1.2–32.8), for weekly oral prophylaxis it was 9.5 (95% CI: 2.4–37.9), and for daily oral
prophylaxis it was 31 (95% CI: 10.2–94.4).
b Dutch and Danish formula-fed infants with biliary atresia receiving oral (not IM) prophylaxis were combined. VKDB was found in 1 of 93, severe VKD in 1 of 93, and VKD in 6 of 93 of these infants.
The risk in formula-fed infants was used to compare the risk in breastfed infants under the 3 prophylactic regimens.
c P values as determined by using Fisher’s exact test were .04 for VKD, .02 for severe VKD, and .19 for VKDB.
d P values were .004 for VKD, .005 for severe VKD, and .23 for VKDB.
e P values were.001 for all of the comparisons.
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population. It also enables a comparison of failure rates
between different subpopulations, such as breastfed in-
fants. Moreover, the availability of biochemical parameters
can be used to establish the risk of a “near miss,” (eg, a
severe VKD diagnosed before a bleeding could develop).
Most importantly, as presently shown, this strategy allows
the detection of differences between regimens in their abil-
ity to protect high-risk populations, which remained un-
detected using surveillance studies.
Comparison of the 2 oral regimens indicates that
1-mg weekly prophylaxis is more effective than 25-g
daily prophylaxis. The most likely explanation for this
observation is the dosage; the cumulative dose per week
was 5 times higher in the weekly regimen (1.00 mg vs
0.18 mg for weekly and daily oral prophylaxis, respec-
tively). It has been hypothesized that a high dosing
frequency may require a relatively low dose of vitamin K
to obtain good efficacy.28 However, our present data do
not support the hypothesis that a daily dose of 25 g is
sufficient.
This study firmly establishes the efficacy of formula
feeding in preventing VKDB in infants with unrecog-
nized cholestasis. Formula feeding is even more effective
than IM prophylaxis, the “gold standard,” to prevent
VKDB. The mechanism underlying the preventive effi-
cacy of formula feeding remains unclear. The vitamin K
content of formula offers an insufficient explanation,
because the average estimated daily intake of vitamin K
in formula in our cohort (based on a daily formula
intake of 150 mL/kg) is 25 to 50 g, similar to the dose
prescribed in the Dutch prophylactic regimen. A higher
production of vitamin K by colonic bacteria in formula-
fed infants might play a role.5 However, even a mixed-
micellar vitamin K formulation, containing bile acids, is
poorly absorbed in infants with biliary atresia.29
Logistic regression revealed that female gender was a
risk factor for VKDB. Although both genders were at a
similar risk to present with a (severe) biochemical VKD,
female infants were at a significantly higher risk of de-
veloping a VKDB. This result has not been reported
previously, and the meaning of this finding is presently
unknown.
CONCLUSIONS
We quantified the efficacy of frequent oral vitamin K
prophylactic regimens in a cohort of Dutch and Danish
biliary atresia infants. Our data clearly indicate that the
current Dutch prophylaxis of 25 g of daily oral vitamin
K is insufficient to protect exclusively breastfed infants
with biliary atresia from VKDB. Effective oral prophy-
laxis is feasible, as shown by the efficacy of a weekly oral
dose of 1 mg of vitamin K in protecting these infants.
Based on these data, the current Dutch prophylactic
regimen is presently being reevaluated. We feel that
nationwide prophylaxis should be tailored to protect
those individuals who are at the highest risk to develop
an adverse event. An event analysis in high-risk popu-
lations, as a means of “postmarketing” surveillance,
could help to achieve this objective.
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